Clinical Trial Update: Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures [Phase 2]

View source ↗

Summary

Phase 2 trial targeting MDMD and PD-1 in tumors with tertiary lymphoid structures has been withdrawn; the study covered soft tissue sarcoma, non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Soft Tissue Sarcoma
• Triple-negative Breast Cancer

Drugs mentioned

• MDMD-targeting agent (MDMD-targeting agent)
• PD-1 inhibitor

Snippet

Sponsor: Institut Bergonié | Conditions: Adult Soft Tissue Sarcoma, Non Small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN